CLAIMS

1. Use of an aptamer comprising SEQ ID NO: 1 for the manufacture of a medicament for reducing the risk of intracranial hemorrhages after an acute ischemic stroke in a subject, wherein the aptamer is to be administered after the acute ischemic stroke at a dose of at least about 0.2 mg/kg, and wherein the administration of the aptamer reduces the risk of intracranial hemorrhages in at least about a 14% with respect to a subject not treated with the aptamer.

2. The use according to claim 1, wherein the intracranial hemorrhages are symptomatic intracranial hemorrhages, and wherein the administration of the aptamer reduces the risk of symptomatic intracranial hemorrhages in at least about a 34% with respect to a subject not treated with the aptamer.

3. Use of an aptamer comprising SEQ ID NO: 1 for the manufacture of a medicament for improving the neurological recovery after an acute ischemic stroke in a subject, wherein the improvement of neurological recovery is mediated by a reduction of the risk of intracranial hemorrhages, wherein the aptamer is to be administered after the acute ischemic stroke at a dose of at least about 0.2 mg/kg, and wherein the aptamer:
(i) reduces the NIHSS score, and
(ii) reduces the mRS score to 0-2,
with respect to a subject not treated with the aptamer.

4. The use according to claim 3, wherein the reduction in the NIHSS score at 72 hours is of at least about 57% with respect to a subject not treated with the aptamer.

5. The use according to any one of claims 3-4, wherein the reduction in the mRS score to 0-2 at 90 days is of at least about 36% with respect to a subject not treated with the aptamer.

6. The use according to any one of claims 1-5, wherein the aptamer reduces brain edema in at least about a 67% with respect to a subject not treated with the aptamer.

7. The use according to any one of claims 1-6, wherein the aptamer is to be administered within about 8 hours from stroke onset, particularly within about 4 hours from stroke onset.

8. The use according to any one of claims 1-7, wherein the aptamer is to be administered in combination with artery recanalization.

9. The use according to claim 8, wherein the aptamer is to be administered in combination with endovascular treatment.

10. The use according to claim 9, wherein the aptamer is to be administered prior or concurrently with the endovascular treatment.

11. The use according to claim 10, wherein the aptamer is to be administered less than about 4 hours prior to endovascular treatment.

12. The use according to any one of claims 8-11, wherein the aptamer is to be administered in combination with pharmacological thrombolysis, particularly the administration of tissue plasminogen activator.

13. The use according to claim 12, wherein the aptamer is to be administered concurrently or after the administration of pharmacological thrombolysis.

14. The use according to any one of claims 1-13, wherein the aptamer is to be administered intravenously by infusion for about 30 minutes.

15. The use according to any one of claims 1-14, wherein the subject:
i) is between about 18 and about 90 years of age;
ii) has a baseline NIHSS of between about 8 points and about 25 points;
iii) has a pre-stroke mRS score of between 0 points and about 2 points;
iv) has an infarct volume of between about 5 cc and about 70 cc;
v) has an occlusion in the terminal internal carotid artery, M1 or M2 segments of the middle cerebral artery;
vi) has a mTICI score of 0 or 1;
vii) has a volume of diffusion-weighted imaging restriction between about 5 mL and about 70 mL;
viii) has an ASPECTS between about 6 and about 10; or
ix) any combination thereof,
at stroke onset.